Optimizing carfilzomib use in multiple myeloma treatment.

Abstract

The treatment landscape of multiple myeloma (MM) continues to evolve. More liberal use of various proteasome inhibitors and immunomodulatory agents is being actualized in Korea, making continuous optimization of MM treatment possible. Amidst it all, the biggest issue in year 2018 was perhaps the insurance coverage of carfilzomib use as second-line treatment, either with dexamethasone or lenalidomide plus dexamethasone. One year into carfilzomib use, we are met with notable improvements and new challenges. Here, I would like to share my center's experience (Fig. 1) with carfilzomib and address some of the issues we are faced with. Open in a separate window Fig. 1 Overview of carfilzomib use at Seoul National University Hospital since 2016. Abbreviations: KRd, carfilzomib, lenalidomide, dexamethasone; Rd, lenalidomide, dexamethasone; tx, treatment; VMP, bortezomib, melphalan, prednisone; VTD, bortezomib, thalidomide, dexamethasone.